For the readers interested in the stock health of Jounce Therapeutics Inc. (JNCE). It is currently valued at $1.00. When the transactions were called off in the previous session, Stock hit the highs of $1.01, after setting-off with the price of $0.95. Company’s stock value dipped to $0.9405 during the trading on the day. When the trading was stopped its value was $0.90.Recently in News on February 23, 2023, Redx and Jounce Announce Recommended Business Combination. Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease. You can read further details here
Jounce Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $7.9400 on 04/05/22, with the lowest value was $0.5773 for the same time period, recorded on 12/13/22.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Jounce Therapeutics Inc. (JNCE) full year performance was -85.96%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Jounce Therapeutics Inc. shares are logging -87.41% during the 52-week period from high price, and 73.20% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.58 and $7.94.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 667269 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Jounce Therapeutics Inc. (JNCE) recorded performance in the market was -9.92%, having the revenues showcasing 37.78% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 54.99M, as it employees total of 137 workers.
Market experts do have their say about Jounce Therapeutics Inc. (JNCE)
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.1914, with a change in the price was noted -1.13. In a similar fashion, Jounce Therapeutics Inc. posted a movement of -53.06% for the period of last 100 days, recording 1,709,665 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for JNCE is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Jounce Therapeutics Inc. (JNCE)
Raw Stochastic average of Jounce Therapeutics Inc. in the period of last 50 days is set at 22.44%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 22.44%. In the last 20 days, the company’s Stochastic %K was 10.57% and its Stochastic %D was recorded 14.78%.
Bearing in mind the latest performance of Jounce Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -9.92%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -69.23%, alongside a downfall of -85.96% for the period of the last 12 months. The shares increased approximately by -7.42% in the 7-day charts and went up by -9.92% in the period of the last 30 days. Common stock shares were driven by 37.78% during last recorded quarter.
